Phase II Dose-finding Study of ASP4070 -A Randomized, Double-blind, Placebo-controlled, Dose-finding Study in Environmental Exposure Chamber in Patients With Cedar Pollinosis

Trial Profile

Phase II Dose-finding Study of ASP4070 -A Randomized, Double-blind, Placebo-controlled, Dose-finding Study in Environmental Exposure Chamber in Patients With Cedar Pollinosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs ASP 4070 (Primary)
  • Indications Allergic rhinoconjunctivitis; Tree pollen hypersensitivity
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 02 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 24 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 02 Apr 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top